Announcement • May 04
Contineum Therapeutics, Inc., Annual General Meeting, Jun 26, 2026 Contineum Therapeutics, Inc., Annual General Meeting, Jun 26, 2026. Price Target Changed • Mar 09
Price target increased by 8.2% to US$22.00 Up from US$20.33, the current price target is an average from 6 analysts. New target price is 62% above last closing price of US$13.54. Stock is up 83% over the past year. The company posted a net loss per share of US$2.17 last year. Recent Insider Transactions Derivative • Feb 27
Chief Science Officer exercised options and sold US$122k worth of stock On the 25th of February, Daniel Lorrain exercised 8k options at a strike price of around US$1.01 and sold these shares for an average price of US$16.02 per share. This trade did not impact their existing holding. Since December 2025, Daniel's direct individual holding has decreased from 171.23k shares to 162.89k. Company insiders have collectively sold US$302k more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Feb 12
President notifies of intention to sell stock Carmine Stengone intends to sell 8k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of February. If the sale is conducted around the recent share price of US$15.75, it would amount to US$118k. For the year to December 2023, Carmine's total compensation was 12% salary and 88% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Carmine has owned 12.86k shares directly. Company insiders have collectively sold US$62k more than they bought, via options and on-market transactions in the last 12 months. New Risk • Jan 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). New Risk • Jan 09
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 37% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Revenue is less than US$1m. Price Target Changed • Jan 08
Price target decreased by 8.3% to US$20.33 Down from US$22.18, the current price target is an average from 6 analysts. New target price is 122% above last closing price of US$9.17. Stock is down 31% over the past year. The company posted a net loss per share of US$2.18 last year. Announcement • Dec 13
Contineum Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $89.999991 million. Contineum Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $89.999991 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Securities Offered: 7,346,938
Price\Range: $12.25
Discount Per Security: $0.735 Announcement • Nov 22
Contineum Therapeutics, Inc. Reports Topline Data from its Phase 2 PIPE-307 Trial for the Treatment of Relapsing-Remitting Multiple SCLEROSIS Contineum Therapeutics, Inc. reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, in development for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The trial demonstrated acceptable safety and tolerability at both doses. The trial did not meet itspecified primary or secondary efficacy endpoints. In RRMS patients, no significant change was observed in binocular 2.5% low contrast letter acuity across treatment arms. The Company continues to interrogate the trial data related to its exploratory endpoints. The VISTA trial was a randomized, double-blind, placebo-controlled, multi-center, proof-of-concept trial designed to evaluate the safety and efficacy of PIPE-307 in RRMS patients and included clinical and imaging endpoints. The Company intends to present the complete dataset at a future medical meeting and to publish full results in a peer-reviewed medical journal. Announcement • Nov 21
Contineum Therapeutics, Inc. Reports Topline Data from Its Phase 2 PIPE-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) Contineum Therapeutics, Inc. reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, in development for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The trial demonstrated acceptable safety and tolerability at both doses. The trial did not meet itspecified primary or secondary efficacy endpoints. In RRMS patients, no significant change was observed in binocular 2.5% low contrast letter acuity across treatment arms. The Company continues to interrogate the trial data related to its exploratory endpoints. The VISTA trial was a randomized, double-blind, placebo-controlled, multi-center, proof-of-concept trial designed to evaluate the safety and efficacy of PIPE-307 in RRMS patients and included clinical and imaging endpoints. The Company intends to present the complete dataset at a future medical meeting and to publish full results in a peer-reviewed medical journal. Announcement • Sep 18
Contineum Therapeutics, Inc. Reports Positive Topline Data from Phase 1b Positron Emission Tomography (Pet) Trial of PIPE-791 Contineum Therapeutics, Inc. announced positive topline data from its PIPE-791 Phase 1b Positron emission tomography (PET) trial. The trial met its primary objectives by demonstrating PIPE-791, the Company's novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 (LPA1) receptor, achieved high brain receptor occupancy (RO) in healthy volunteers and progressive multiple sclerosis (PrMS) patients with a clear pharmacokinetic (PK) correlation between drug exposure and receptor engagement. Based on these data, the Company believes its planned doses for its future Phase 2 proof-of-concept clinical trials in idiopathic pulmonary fibrosis (IPF) and PrMS will exceed 90% target coverage at trough with once daily dosing. The Company believes its planned doses for the future Phase 2 proof-of the concept clinical trials will exceed 90% target coverage At trough with once daily dosing; The Company believes its planned dose selection for its future Phase 2proof-of-concept clinical trials will achieve sustained or exceed 90% target coverage at bottom with once daily dosing; the Company's cash runway; the indications, anticipated benefits of, and market opportunities for the Company's drug candidates; the Company's business strategies and plans; and the quotations of the Company's management. These risks and uncertainties, include, but are not limited to, the following: the Company is heavily dependent on the success of PIPE-791 and PIPE-307, both of which are in the early stages of clinical development, and neither of these drug candidates may progress through clinical development or receive regulatory approval; the results of earlier preclinical studies and clinical trials, including those conducted by third parties, may not be predictive of future results and unexpected adverse side effects or inadequate efficacy of the Company's drug candidates may limit their development, regulatory approval and/or commercialization; the timing and outcome of research, development and regulatory review is uncertain; the U.S. Food & Drug Administration or comparable foreign regulatory authorities may differ as to the design or implementation of proposed clinical trials; clinical trials and preclinical studies may not proceed at the time or in the manner expected, or at all; the potential for the Company's programs and prospects to be negatively impacted by developments relating to the Company's competitors, including the results of studies or regulatory determinations relating to the Company's competitors; risks associated with reliance on third parties to successfully conduct clinical trials and, in the case of PIPE-307, the Company's reliance, pursuant to a global license and development agreement, upon Janssen Pharmaceutica NV, a Johnson & Johnson company, to develop PIPE-307 for any other indication other than relapsing-remitting multiple sclerosis and, after completion of the Company's PIPE-307 Phase 2 VISTA trial, Janssen Pharmaceutico NV's decision, in its sole discretion, whether or not to further develop PIPE-307 For relapsing-remitting Multiple sclerosis; the Company has incurred significant operating expenses since inception and the Company has incurred significant operating costs since inception and the Company's ongoing ongoing ongoing ongoing trials. Announcement • Jun 25
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography Trial of PIPE-791 Contineum Therapeutics, Inc. announced an update on its Phase 1b positron emission Tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer and progressive multiple sclerosis (PrMS) cohorts of this trial. This trial builds on compelling preclinical data and improves understanding of receptor occupancy in healthy volunteers and patients, helping guide dose selection in the next stages of clinical development. New Risk • Jun 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$94.4m market cap). New Risk • May 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$90.8m market cap). Announcement • May 15
Contineum Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Contineum Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering New Risk • May 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$98.8m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 100% over the past year. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (US$98.8m market cap). Announcement • May 01
Contineum Therapeutics, Inc., Annual General Meeting, Jun 26, 2025 Contineum Therapeutics, Inc., Annual General Meeting, Jun 26, 2025. Announcement • Apr 29
Contineum Therapeutics, Inc. Announces Executive Changes Contineum Therapeutics, Inc. announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company’s executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company’s Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. Dr. Watkins has substantial executive leadership experience spanning the biopharma and academic sectors. Over the past decade, Dr. Watkins advanced to senior level roles at Gilead Sciences, Inc. (NASDAQ: GILD), ultimately serving as the Vice President and Therapeutic Area Head for Inflammation, Clinical Development. In this role, he oversaw assets spanning a broad portfolio including therapeutics directed towards IPF and advanced metabolic dysfunction-associated steatohepatitis. Dr. Watkins expertise spans all stages of clinical development including late-stage programs linked to global registration and commercialization. He has also managed strategic business partnerships with both established pharmaceutical companies and emerging biotech enterprises. Prior to his tenure at Gilead Sciences, Dr. Watkins held an academic career within the Division of Pulmonary and Critical Care Medicine at the University of Washington and the Research Institute of Bloodworks Northwest in Seattle, WA. He focused on clinical and translational research programs in severe lung disease and critical illness. He holds a B.S. in Biology from Ohio University, an M.D. from The Ohio State University and a Master of Science in Public Heath – Epidemiology from the University of Washington. Announcement • Mar 18
Contineum Therapeutics, Inc. Announces Appointment of Diego Miralles to Its Board of Directors Contineum Therapeutics, Inc. announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. Dr. Miralles has served as Chief Executive Officer at AZURNA Therapeutics, Inc., a private pharmaceutical development company, since January 2024. From December 2020 to September 2022, Dr. Miralles was Chief Executive Officer at Laronde Inc., an early-stage biotechnology company. From August 2017 to September 2020, Dr. Miralles served as Chief Executive Officer at Vividion Therapeutics, Inc., a private biopharmaceutical company. From October 2007 to March 2016, Dr. Miralles held executive positions of increasing responsibility leading various research and clinical development programs at Johnson & Johnson. Dr. Miralles has served on the board of directors of Artiva Biotherapeutics, Inc., a publicly traded biotechnology company, since May 2024 and in January 2025, he was appointed as chair of the Clinical Strategy Committee. Dr. Miralles has also been a member of the board of directors at Rady Children’s Institute for Genomic Medicine since 2008 and served as a member of the board of directors at NeuBase Therapeutics, Inc., a public biopharmaceutical company, from April 2019 to April 2021. Dr. Miralles received his M.D. degree from the University of Buenos Aires, his residency in Internal Medicine at the Mayo Clinic and fellowship in Infectious Diseases at The New York Hospital/Cornell University and was on the faculty at Duke University. Announcement • Mar 05
Contineum Therapeutics, Inc. Initiates Patient Dosing in Phase 1B Chronic Pain Trial of Pipe-791 Contineum Therapeutics, Inc. initiated patient dosing in its exploratory PIPE-791 Phase 1b, randomized, double-blind, placebo-controlled, crossover, chronic pain trial. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R). PIPE-791 is being evaluated for the treatment of chronic pain associated with two separate indications, osteoarthritis and low back pain. The Company expects to enroll approximately 40 patients at up to five sites in the U.S., and a treatment duration of 28 days. Contineum anticipates topline data from the PIPE-791 Phase 1b chronic pain trial in early 2026. Chronic pain is often associated with neuropathic symptoms caused by aberrant signaling in the central nervous system leading to heightened sensitivity to painful stimuli. LPA1 activation has been shown preclinically to contribute to persistent hypersensitivity, characteristic of neuropathic pain, by promoting the demyelination of nerve fibers, increasing neuronal excitability and enhancing neuroinflammatory responses in the CNS. By selectively blocking LPA1 receptor activity, an LPA1 antagonist could modify the maladaptive changes in the CNS and subsequently reduce pain. Announcement • Jan 09
Contineum Therapeutics, Inc. Completes Enrollment in Phase 2 PIPE-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) Contineum Therapeutics, Inc. announced that it has completed the targeted enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial. PIPE-307 is a potentially first-in-class M1 receptor antagonist in development for patients with relapsing-remitting multiple sclerosis (RRMS). The Phase 2, randomized, double-blind, placebo-controlled, multi-center, proof-of-concept trial of PIPE-307 will assess safety and efficacy in RRMS patients. The trial is designed to measure multiple clinical and imaging endpoints sensitive to changes in remyelination in RRMS. Contineum anticipates that the last patient will complete the PIPE-307 VISTA trial in the third quarter of 2025. PIPE-307 is being developed pursuant to a global license and development agreement between Contineum and Janssen Pharmaceutica NV, a Johnson & Johnson company. Announcement • Dec 17
Contineum Therapeutics, Inc. Initiates Patient Dosing in Phase 1B Positron Emission Tomography (PET) Trial of PIPE-791 Contineum Therapeutics, Inc. announced dosing of the first cohort of patients in the PIPE-791 Phase 1b positron emission tomography (PET) trial. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R). The Phase 1b, open label, single-center trial is expected to measure the correlation of pharmacokinetics to receptor occupancy by PET imaging in healthy volunteers, as well as idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS) patients. Contineum anticipates topline data from the PIPE-791 Phase 1b PET trial in the second quarter of 2025. Announcement • Nov 19
Contineum Therapeutics Expands Clinical Development of Pipe-791 with Fda Authorization of Its Investigational New Drug Application for Chronic Pain Contineum Therapeutics, Inc. announced authorization of its Investigational New Drug application from the U.S. Food and Drug Administration for PIPE-791 for the treatment of chronic pain associated with two separate indications, osteoarthritis and low back pain. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor. The exploratory Phase 1b, randomized, double-blind, placebo-controlled, crossover, multi-center study is expected to begin in the first quarter of 2025. The Company expects to enroll approximately 40 patients at up to five sites, and a treatment duration of 28 days. Contineum anticipates topline data from the PIPE-791 Phase 1b chronic pain study in early 2026. Chronic pain is often associated with neuropathic symptoms caused by aberrant signaling in the central nervous system leading to heightened sensitivity to painful stimuli. LPA1 activation has been shown to contribute to persistent hypersensitivity, characteristic of neuropathic pain, by promoting the demyelination of nerve fibers, increasing neuronal excitability and enhancing neuroinflammatory responses in the CNS (Company research, Ueda 2020). By selectively blocking LPA1 receptor activity, an LPA1 antagonist may prevent or reverse the maladaptive changes in the nervous system that initiate and maintain the chronic pain state. OA is the most common joint disease characterized by chronic pain and decreased mobility. OA affects approximately 33 million people in the United States. Current pharmacological treatments for pain associated with OA consist of non-steroidal anti-inflammatory drugs, topical agents, antidepressants and steroid injections. LBP is a common musculoskeletal condition that can be associated with spinal degeneration, nerve compression and inflammation. Low back pain affects approximately 45 million people in the United States. Over-the-counter or prescription NSAIDs, antidepressants, steroid injections, muscle relaxants and opioids are commonly used for pain and inflammation reduction. With the addition of the PIPE-791 Phase 1b chronic pain study, the Company continues to expect its cash, cash equivalents and marketable securities of $213.9 million as of September 30, 2024, are sufficient to fund its planned operations through 2027. New Risk • Aug 14
New major risk - Revenue and earnings growth Revenue has declined by 100% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 100% over the past year. Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Announcement • Aug 01
Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307 Contineum Therapeutics, Inc. announced encouraging preclinical data on PIPE-307,a potentially first-in-class M1 receptor antagonist in development for patients with relapse-remitting multiple sclerosis (RRMS), were published online in the peer-reviewed journal, Proceedings of the National Academy of Science (PNAS). RRMS is the most common form of multiple sclerosis (MS). The pathological hallmark of all forms of MS is the accumulation of demyelinating lesions that occur in the brain and spinal cord. In healthy neurons, myelin, which is a specialized extension of the plasma membrane of oligodendrocytes, serves as an insulator that allows for rapid and efficient conduction of electrochemical signals along the axon. In demyelinating diseases, such as MS, loss of myelin leads to slower signal transmission through the axon and eventual permanent loss of neuronal function. The published data highlight the foundational preclinical profile of PIPE-307 that supports Contineum’s ongoing Phase 2 clinical trial in RRMS. To date, Contineum has completed two Phase 1 clinical trials of PIPE-307 in healthy volunteers and has initiated a Phase 2 multi-center, randomized, double-blind, placebo-controlled proof-of-concept clinical trial in RRMS patients (NCT06083753). This trial, named VISTA, will assess efficacy and safety in patients with RRMS and is designed to measure multiple clinical and imaging endpoints sensitive to changes in remyelination in RRMS. PIPE-307 is being developed pursuant to a global license and development agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Announcement • Jun 25
Contineum Therapeutics, Inc. Appoints Sarah Boyce as Independent Member of its Board of Directors Contineum Therapeutics, Inc. announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc., as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum’s board. Ms. Boyce has extensive expertise in global pharmaceutical product development and commercialization, business operations, strategic planning and execution, and has a proven track record of successfully bringing over 20 products to market and scaling companies. Currently, Ms. Boyce serves as President and Chief Executive Officer and as a member of the Board of Directors of Avidity Biosciences, Inc. Prior to joining Avidity, Ms. Boyce served as a Director and President of Akcea Therapeutics, Inc., and as Chief Business Officer at Ionis Pharmaceuticals, Inc., where she was responsible for business development, alliance management, patient advocacy and investor relations. Before Ionis, Ms. Boyce served as Vice President, Head of International Business Strategy and Operations at Forest Laboratories, Inc., and held various positions of increasing responsibility with Alexion Pharmaceuticals Inc., Novartis Group AG, Bayer AG and F. Hoffmann-La Roche AG. Ms. Boyce also previously served on the Board of Directors of Berkeley Lights Inc. and currently serves on the board of directors of OmniAb, Inc. Ms. Boyce received a B.S. degree in microbiology from the University of Manchester, England. Announcement • Jun 05
Contineum Therapeutics, Inc. Appoints John Healy as General Counsel & Corporate Secretary Contineum Therapeutics, Inc. announced the appointment of John Healy as General Counsel & Corporate Secretary. Mr. Healy is a business and transactional attorney with over two decades of experience in the biotechnology industry, including as a corporate associate within top tier law firms, as a public company general counsel and as a trusted legal advisor providing a broad range of legal consulting support to the executive management teams of his private and public consulting clients. He joins Contineum after serving as General Counsel & Corporate Secretary at the public biotechnology company, Tyra Biosciences, Inc., where he served on the executive management team and was responsible for all company legal matters, including overseeing the company’s IPO in late 2021 and transition to becoming a public company. Additionally, for more than a decade, Mr. Healy has been a legal consultant to numerous privately held and publicly traded clients within the life sciences industry, including Contineum, providing executive level counsel and advice to senior management teams, boards of directors and company departments on legal matters through the full corporate life cycle from early stage through research, product formulation and manufacturing, pre-clinical/clinical development to initial public offering or corporate acquisition. Prior to his consulting practice, Mr. Healy served as General Counsel & Secretary for Hollis-Eden Pharmaceuticals, a publicly traded biotechnology company. Mr. Healy began his career supporting life sciences and emerging growth companies as a corporate, transactional and securities attorney at national law firms including tenures at Brobeck, Phleger & Harrison, Clifford Chance and Latham & Watkins. Mr. Healy received his J.D. from the University of San Diego School of Law and a B.A. from the University of California, Berkeley. Announcement • May 23
Contineum Therapeutics, Inc. Appoints Troy Ignelzi as Independent Member of Its Board of Directors and as Chair of the Audit Committee Contineum Therapeutics, Inc. announced the appointment of Troy Ignelzi as an independent member of its Board of Directors and as Chair of the Audit Committee. Mr. Ignelzi brings nearly two decades of financial leadership and industry experience to Contineum’s board. Currently, Mr. Ignelzi serves as the Chief Financial Officer at Rapport Therapeutics, Inc., a precision neuromedicines company, where he has served since November 2023. Prior to that, he was Chief Financial Officer at Karuna Therapeutics, Inc., a neurological disease company (acquired by Bristol Myers Squibb), where he led the team in the execution of a private crossover round, the company’s IPO and multiple follow-on financings. Prior to Karuna, Mr. Ignelzi served as Chief Financial Officer at Juventas Therapeutics and scPharmaceuticals. Mr. Ignelzi began his career at Eli Lilly, and then held roles of increasing responsibility at several biotechnology companies including Esperion Therapeutics, Inc. and Insys Therapeutics, Inc. Previously, Mr. Ignelzi served on the board of CinCor Pharma, Inc., where he advised on the company’s sale to AstraZeneca in early 2023. He currently serves on the boards of Vedanta Biosciences and Abivax and is an Executive Advisor for Sofinnova Investments. Mr. Ignelzi is a graduate of Ferris State University, where he earned his B.S. in accounting. 
